Sandoz (SDZ) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
28 Oct, 2026Executive summary
Q3 net sales were USD 2.942bn, up 5% at constant currencies (CC), or 7% excluding the anti-infective B2B impact; the 20th consecutive quarter of net sales growth.
Biosimilars grew 17% at CC and reached 34% of Q3 sales; strong volume demand offset price headwinds.
Financial highlights
9M net sales were USD 8.703bn, up 8% in USD and 5% at CC; underlying CC growth was 6% excluding the anti-infective B2B impact.
9M volume growth was 10%, partly offset by 5% price erosion; FX contributed USD 0.2bn against a USD 0.4bn price impact.
Q3 biosimilar sales grew 17% at CC to USD 998m; generics were flat, or up 2% excluding the anti-infective B2B impact.
Outlook and guidance
FY26 net-sales growth guidance narrowed to 5%-6% at CC from mid-to-high single digits; Q4 growth is expected to step up versus Q3.
Core EBITDA margin guidance rose to 23.0%-23.5%, versus 21.7% in 2025; core EPS expectations also increased.
Assumptions include mid-single-digit price erosion, no material generic semaglutide sales contribution in 2026, and a +2 percentage-point spot-FX impact on sales with no material margin impact.
Long-term targets include mid-to-high-single-digit net-sales CAGR at CC for 2025-2030, core EBITDA margin of 25%-27% by 2030, and more than doubling 2035 net sales versus 2025 with margin above 30%, excluding GLP-1 upside.
Bio100 targets 100+ biosimilars by 2040; management expressed confidence in 2027 and supports consensus growth of ~5.5% at comparable currencies but has not issued FY27 guidance.
Latest events from Sandoz
- Biosimilar scale-up, launches and internal supply underpin the 2035 growth ambition.SDZ
Jefferies Global Healthcare Conference - Bio 100 targets over 100 biosimilars by 2040, doubling net sales and margin above 30% by 2035.SDZ
CMD 2026 - Biosimilars drove 5% sales growth and margin expansion, confirming a strong full-year outlook.SDZ
Q2 2026 - Biosimilars drove Q1 2026 growth, offsetting generics decline; guidance reaffirmed.SDZ
Q1 2026 TU - Biosimilars drove 5% sales growth and a margin upgrade, now at 31% of Q3 net sales.SDZ
Q3 2025 TU - Strong pipeline, biosimilar launches, and operational gains drive margin and global growth.SDZ
Sandoz Strategic Review 2024 - Q3 sales up 12% and biosimilars up 32%, prompting raised full-year guidance.SDZ
Q3 2024 - Strong 2023 growth, pipeline expansion, and margin targets drive future biosimilars leadership.SDZ
43rd Annual J.P. Morgan Healthcare Conference 2025 - Biosimilars fueled record sales and margin growth in 2024, supporting a strong outlook for 2025.SDZ
Q4 2024